PET of tumor CXCR4 expression with 4-18F-T140

Journal of Nuclear Medicine

Volumn 51, Issue 11, 2010, Pages 1796-1804

  Jacobson, Orit ^a   Weiss, Ido D ^b   Kiesewetter, Dale O ^a   Farber, Joshua M ^b   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

18F fluoride; CXCR4; PET; T140 peptide

Indexed keywords

4 BENZOYL TN14003 F 18; AMINO ACID; CHEMOKINE RECEPTOR CXCR4; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CHO CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; ERYTHROCYTE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CHO CELLS; CRICETINAE; CRICETULUS; FLUORINE RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; MICE; NEOPLASMS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RECEPTORS, CXCR4;

EID: 79851474977     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.079418     Document Type: Article

References (33)

1. Klein RS, Rubin JB. Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol. 2004;25:306-314.
2. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 2001;12:313-335.
3. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003;167:1676-1686.
4. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14:171-179.
5. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci. 2005;96:317-322.
6. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
7. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832-1837.
8. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003;100:13513-13518.
9. Redjal N, Chan JA, Segal RA, Kung AL. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006;12:6765-6771.
10. Lee HJ, Kim SW, Kim HY, et al. Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer. Int J Oncol. 2009;34:473-480.
11. Oda Y, Tateishi N, Matono H, et al. Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer. 2009;124:1852-1859.
12. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113:4341-4351.
13. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604-4613.
14. Zeng Z, Samudio IJ, Munsell M, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 2006;5:3113-3121.
15. Li JK, Yu L, Shen Y, Zhou LS, Wang YC, Zhang JH. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol. 2008;14:2308-2313.
16. Yoon Y, Liang Z, Zhang X, et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res. 2007;67:7518-7524.
17. 64Cu-AMD3100: a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem. 2009;17:1486-1493.
18. 64Cu]AMD3100 positron emission tomography. Cancer Res. 2010;70:3935-3944.
19. Lang L, Jagoda E, Schmall B, et al. Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem. 1999;42:1576-1586.
20. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
21. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA. 1999;96:5215-5220.
22. Tamamura H, Omagari A, Hiramatsu K, et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett. 2001;11:1897-1902.
23. Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003;550:79-83.
24. Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev. 2010;110:3087-3111.
25. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43-52.
26. Tamamura H, Hiramatsu K, Mizumoto M, et al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org Biomol Chem. 2003;1:3663-3669.
27. Abraham M, Beider K, Wald H, et al. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia. 2009;23:1378-1388.
28. 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006;33:489-494.
29. Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med. 2009;50:1124-1130.
30. Nickles RJ, Gatley SJ, Votaw JR, Kornguth ML. Production of reactive fluorine-18. Int J Rad Appl Instrum [A]. 1986;37:649-661.
31. McQuade P, Rowland DJ, Lewis JS, Welch MJ. Positron-emitting isotopes produced on biomedical cyclotrons. Curr Med Chem. 2005;12:807-818.
32. Jacobson O, Chen X. PET designated flouride-18 production and chemistry. Curr Top Med Chem. 2010;10:1048-1059.
33. Rot A. Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev. 2005;16:687-694.